Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass

We investigated whether the administration of enoximone during and after cardiopulmonary bypass (CPB) improves splanchnic oxygen utilization and thereby gut mucosal integrity in humans by its vasodilating and inotropic properties. Surgical intensive care unit (ICU) in a university hospital. 21 patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Intensive care medicine 1997-03, Vol.23 (3), p.267-275
Hauptverfasser: LOICK, H. M, MÖLLHOFF, T, BERENDES, E, HAMMEL, D, VAN AKEN, H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 275
container_issue 3
container_start_page 267
container_title Intensive care medicine
container_volume 23
creator LOICK, H. M
MÖLLHOFF, T
BERENDES, E
HAMMEL, D
VAN AKEN, H
description We investigated whether the administration of enoximone during and after cardiopulmonary bypass (CPB) improves splanchnic oxygen utilization and thereby gut mucosal integrity in humans by its vasodilating and inotropic properties. Surgical intensive care unit (ICU) in a university hospital. 21 patients (ASA III classification) scheduled for elective coronary artery bypass grafting were enrolled in the study. After induction of general anesthesia, patients were randomly assigned to received a bolus of 0.2 mg/kg enoximone, followed by 5 microg/kg per min (enoximone group), or followed by an equal volume of saline (NaCl group) during and 24 h after the surgical procedure. The following parameters were evaluated at different time intervals: systemic and pulmonary hemodynamics, blood gas analysis of arterial, mixed venous, and liver venous blood, venous and liver venous lactate level, venous and liver venous endotoxin level and intramucosal partial pressure of carbon dioxide for calculation of intramucosal pH (pHi). Enoximone raised cardiac output and oxygen delivery to higher levels than those observed in the NaCl group. In both groups, gastric pHi fell continuously during the study period. The values were significantly decreased 12 h following admission to the ICU. Endotoxin was not detectable at baseline. Both groups showed increased endotoxin levels, with the highest values during the first 6 h postoperatively. The hepatic venous endotoxin level was almost doubled in the NaCl group in comparison to the enoximone group. Endotoxin levels differed in the two groups 6 and 12 h after admission to the ICU. Improvement of oxygen delivery by enoximone did not prevent gastric mucosal acidosis following CPB. However, since the increase in endotoxin levels in liver venous blood was diminished by using enoximone, the drug seems to have a beneficial effect on tissue damage and barrier function of the gut.
doi_str_mv 10.1007/s001340050327
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78908638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78908638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-99b54e9513dcf6abed34f583d2fd4ac086f447fc88159f6f19e68c428c7917533</originalsourceid><addsrcrecordid>eNp90U1LHTEUBuAgit6qyy4LAUvpZmq-J7Ms0g9BcGPXQ27mxEYyyZjMUG_7583gRWgXXYVDnpxwzovQW0o-UULay0II5YIQSThrD9CGCs4ayrg-RBvCBWuEEuwEvSnlocpWSXqMjjuiOWN6g_5cRxcWiBZwchhievJjirWIuOzKDKO32MQBlymYaH_GWqan3T1EvMw--N9m9pWuAuKQ5vo84gwBTAHsUgjpl4_32Jo8-DQtofY2eYe3u8mUcoaOnAkFzvfnKfrx9cvd1ffm5vbb9dXnm8ZySuam67ZSQCcpH6xTZgsDF05qPjA3CGOJVk6I1lmtqeyccrQDpa1g2rYdbSXnp-jDS98pp8cFytyPvlgIdSJIS-lbXdehuK7w43_hulVKNBErvfiHPqQlxzpGTwlltMah15-bF2VzKiWD66fsx7qBivo1vf6v9Kp_t--6bEcYXvU-rnr_fn9vijXB5ZqJL6-MKcKlkvwZSpOizw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1012105083</pqid></control><display><type>article</type><title>Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>LOICK, H. M ; MÖLLHOFF, T ; BERENDES, E ; HAMMEL, D ; VAN AKEN, H</creator><creatorcontrib>LOICK, H. M ; MÖLLHOFF, T ; BERENDES, E ; HAMMEL, D ; VAN AKEN, H</creatorcontrib><description>We investigated whether the administration of enoximone during and after cardiopulmonary bypass (CPB) improves splanchnic oxygen utilization and thereby gut mucosal integrity in humans by its vasodilating and inotropic properties. Surgical intensive care unit (ICU) in a university hospital. 21 patients (ASA III classification) scheduled for elective coronary artery bypass grafting were enrolled in the study. After induction of general anesthesia, patients were randomly assigned to received a bolus of 0.2 mg/kg enoximone, followed by 5 microg/kg per min (enoximone group), or followed by an equal volume of saline (NaCl group) during and 24 h after the surgical procedure. The following parameters were evaluated at different time intervals: systemic and pulmonary hemodynamics, blood gas analysis of arterial, mixed venous, and liver venous blood, venous and liver venous lactate level, venous and liver venous endotoxin level and intramucosal partial pressure of carbon dioxide for calculation of intramucosal pH (pHi). Enoximone raised cardiac output and oxygen delivery to higher levels than those observed in the NaCl group. In both groups, gastric pHi fell continuously during the study period. The values were significantly decreased 12 h following admission to the ICU. Endotoxin was not detectable at baseline. Both groups showed increased endotoxin levels, with the highest values during the first 6 h postoperatively. The hepatic venous endotoxin level was almost doubled in the NaCl group in comparison to the enoximone group. Endotoxin levels differed in the two groups 6 and 12 h after admission to the ICU. Improvement of oxygen delivery by enoximone did not prevent gastric mucosal acidosis following CPB. However, since the increase in endotoxin levels in liver venous blood was diminished by using enoximone, the drug seems to have a beneficial effect on tissue damage and barrier function of the gut.</description><identifier>ISSN: 0342-4642</identifier><identifier>EISSN: 1432-1238</identifier><identifier>DOI: 10.1007/s001340050327</identifier><identifier>PMID: 9083228</identifier><identifier>CODEN: ICMED9</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Aged ; Analysis of Variance ; Biological and medical sciences ; Blood Gas Analysis ; Cardiac Output - drug effects ; Cardiopulmonary Bypass ; Cardiotonic agents ; Cardiotonic Agents - administration &amp; dosage ; Cardiotonic Agents - pharmacology ; Cardiovascular system ; Catheters ; Coronary vessels ; Endotoxins - blood ; Enoximone - administration &amp; dosage ; Enoximone - pharmacology ; Female ; Fentanyl ; Heart surgery ; Hemodynamics - drug effects ; Humans ; Hydrogen-Ion Concentration ; Hypotheses ; Intensive care ; Lactates - blood ; Liver ; Male ; Medical sciences ; Middle Aged ; Oxygen Consumption - drug effects ; Patients ; Pharmacology. Drug treatments ; Pulmonary arteries ; Random Allocation ; Splanchnic Circulation - drug effects ; Surgical apparatus &amp; instruments ; Veins &amp; arteries</subject><ispartof>Intensive care medicine, 1997-03, Vol.23 (3), p.267-275</ispartof><rights>1997 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c310t-99b54e9513dcf6abed34f583d2fd4ac086f447fc88159f6f19e68c428c7917533</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2603565$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9083228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LOICK, H. M</creatorcontrib><creatorcontrib>MÖLLHOFF, T</creatorcontrib><creatorcontrib>BERENDES, E</creatorcontrib><creatorcontrib>HAMMEL, D</creatorcontrib><creatorcontrib>VAN AKEN, H</creatorcontrib><title>Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass</title><title>Intensive care medicine</title><addtitle>Intensive Care Med</addtitle><description>We investigated whether the administration of enoximone during and after cardiopulmonary bypass (CPB) improves splanchnic oxygen utilization and thereby gut mucosal integrity in humans by its vasodilating and inotropic properties. Surgical intensive care unit (ICU) in a university hospital. 21 patients (ASA III classification) scheduled for elective coronary artery bypass grafting were enrolled in the study. After induction of general anesthesia, patients were randomly assigned to received a bolus of 0.2 mg/kg enoximone, followed by 5 microg/kg per min (enoximone group), or followed by an equal volume of saline (NaCl group) during and 24 h after the surgical procedure. The following parameters were evaluated at different time intervals: systemic and pulmonary hemodynamics, blood gas analysis of arterial, mixed venous, and liver venous blood, venous and liver venous lactate level, venous and liver venous endotoxin level and intramucosal partial pressure of carbon dioxide for calculation of intramucosal pH (pHi). Enoximone raised cardiac output and oxygen delivery to higher levels than those observed in the NaCl group. In both groups, gastric pHi fell continuously during the study period. The values were significantly decreased 12 h following admission to the ICU. Endotoxin was not detectable at baseline. Both groups showed increased endotoxin levels, with the highest values during the first 6 h postoperatively. The hepatic venous endotoxin level was almost doubled in the NaCl group in comparison to the enoximone group. Endotoxin levels differed in the two groups 6 and 12 h after admission to the ICU. Improvement of oxygen delivery by enoximone did not prevent gastric mucosal acidosis following CPB. However, since the increase in endotoxin levels in liver venous blood was diminished by using enoximone, the drug seems to have a beneficial effect on tissue damage and barrier function of the gut.</description><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Blood Gas Analysis</subject><subject>Cardiac Output - drug effects</subject><subject>Cardiopulmonary Bypass</subject><subject>Cardiotonic agents</subject><subject>Cardiotonic Agents - administration &amp; dosage</subject><subject>Cardiotonic Agents - pharmacology</subject><subject>Cardiovascular system</subject><subject>Catheters</subject><subject>Coronary vessels</subject><subject>Endotoxins - blood</subject><subject>Enoximone - administration &amp; dosage</subject><subject>Enoximone - pharmacology</subject><subject>Female</subject><subject>Fentanyl</subject><subject>Heart surgery</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Hypotheses</subject><subject>Intensive care</subject><subject>Lactates - blood</subject><subject>Liver</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Oxygen Consumption - drug effects</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Pulmonary arteries</subject><subject>Random Allocation</subject><subject>Splanchnic Circulation - drug effects</subject><subject>Surgical apparatus &amp; instruments</subject><subject>Veins &amp; arteries</subject><issn>0342-4642</issn><issn>1432-1238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp90U1LHTEUBuAgit6qyy4LAUvpZmq-J7Ms0g9BcGPXQ27mxEYyyZjMUG_7583gRWgXXYVDnpxwzovQW0o-UULay0II5YIQSThrD9CGCs4ayrg-RBvCBWuEEuwEvSnlocpWSXqMjjuiOWN6g_5cRxcWiBZwchhievJjirWIuOzKDKO32MQBlymYaH_GWqan3T1EvMw--N9m9pWuAuKQ5vo84gwBTAHsUgjpl4_32Jo8-DQtofY2eYe3u8mUcoaOnAkFzvfnKfrx9cvd1ffm5vbb9dXnm8ZySuam67ZSQCcpH6xTZgsDF05qPjA3CGOJVk6I1lmtqeyccrQDpa1g2rYdbSXnp-jDS98pp8cFytyPvlgIdSJIS-lbXdehuK7w43_hulVKNBErvfiHPqQlxzpGTwlltMah15-bF2VzKiWD66fsx7qBivo1vf6v9Kp_t--6bEcYXvU-rnr_fn9vijXB5ZqJL6-MKcKlkvwZSpOizw</recordid><startdate>19970301</startdate><enddate>19970301</enddate><creator>LOICK, H. M</creator><creator>MÖLLHOFF, T</creator><creator>BERENDES, E</creator><creator>HAMMEL, D</creator><creator>VAN AKEN, H</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>19970301</creationdate><title>Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass</title><author>LOICK, H. M ; MÖLLHOFF, T ; BERENDES, E ; HAMMEL, D ; VAN AKEN, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-99b54e9513dcf6abed34f583d2fd4ac086f447fc88159f6f19e68c428c7917533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Blood Gas Analysis</topic><topic>Cardiac Output - drug effects</topic><topic>Cardiopulmonary Bypass</topic><topic>Cardiotonic agents</topic><topic>Cardiotonic Agents - administration &amp; dosage</topic><topic>Cardiotonic Agents - pharmacology</topic><topic>Cardiovascular system</topic><topic>Catheters</topic><topic>Coronary vessels</topic><topic>Endotoxins - blood</topic><topic>Enoximone - administration &amp; dosage</topic><topic>Enoximone - pharmacology</topic><topic>Female</topic><topic>Fentanyl</topic><topic>Heart surgery</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Hypotheses</topic><topic>Intensive care</topic><topic>Lactates - blood</topic><topic>Liver</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Oxygen Consumption - drug effects</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Pulmonary arteries</topic><topic>Random Allocation</topic><topic>Splanchnic Circulation - drug effects</topic><topic>Surgical apparatus &amp; instruments</topic><topic>Veins &amp; arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LOICK, H. M</creatorcontrib><creatorcontrib>MÖLLHOFF, T</creatorcontrib><creatorcontrib>BERENDES, E</creatorcontrib><creatorcontrib>HAMMEL, D</creatorcontrib><creatorcontrib>VAN AKEN, H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Intensive care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LOICK, H. M</au><au>MÖLLHOFF, T</au><au>BERENDES, E</au><au>HAMMEL, D</au><au>VAN AKEN, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass</atitle><jtitle>Intensive care medicine</jtitle><addtitle>Intensive Care Med</addtitle><date>1997-03-01</date><risdate>1997</risdate><volume>23</volume><issue>3</issue><spage>267</spage><epage>275</epage><pages>267-275</pages><issn>0342-4642</issn><eissn>1432-1238</eissn><coden>ICMED9</coden><abstract>We investigated whether the administration of enoximone during and after cardiopulmonary bypass (CPB) improves splanchnic oxygen utilization and thereby gut mucosal integrity in humans by its vasodilating and inotropic properties. Surgical intensive care unit (ICU) in a university hospital. 21 patients (ASA III classification) scheduled for elective coronary artery bypass grafting were enrolled in the study. After induction of general anesthesia, patients were randomly assigned to received a bolus of 0.2 mg/kg enoximone, followed by 5 microg/kg per min (enoximone group), or followed by an equal volume of saline (NaCl group) during and 24 h after the surgical procedure. The following parameters were evaluated at different time intervals: systemic and pulmonary hemodynamics, blood gas analysis of arterial, mixed venous, and liver venous blood, venous and liver venous lactate level, venous and liver venous endotoxin level and intramucosal partial pressure of carbon dioxide for calculation of intramucosal pH (pHi). Enoximone raised cardiac output and oxygen delivery to higher levels than those observed in the NaCl group. In both groups, gastric pHi fell continuously during the study period. The values were significantly decreased 12 h following admission to the ICU. Endotoxin was not detectable at baseline. Both groups showed increased endotoxin levels, with the highest values during the first 6 h postoperatively. The hepatic venous endotoxin level was almost doubled in the NaCl group in comparison to the enoximone group. Endotoxin levels differed in the two groups 6 and 12 h after admission to the ICU. Improvement of oxygen delivery by enoximone did not prevent gastric mucosal acidosis following CPB. However, since the increase in endotoxin levels in liver venous blood was diminished by using enoximone, the drug seems to have a beneficial effect on tissue damage and barrier function of the gut.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>9083228</pmid><doi>10.1007/s001340050327</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0342-4642
ispartof Intensive care medicine, 1997-03, Vol.23 (3), p.267-275
issn 0342-4642
1432-1238
language eng
recordid cdi_proquest_miscellaneous_78908638
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Aged
Analysis of Variance
Biological and medical sciences
Blood Gas Analysis
Cardiac Output - drug effects
Cardiopulmonary Bypass
Cardiotonic agents
Cardiotonic Agents - administration & dosage
Cardiotonic Agents - pharmacology
Cardiovascular system
Catheters
Coronary vessels
Endotoxins - blood
Enoximone - administration & dosage
Enoximone - pharmacology
Female
Fentanyl
Heart surgery
Hemodynamics - drug effects
Humans
Hydrogen-Ion Concentration
Hypotheses
Intensive care
Lactates - blood
Liver
Male
Medical sciences
Middle Aged
Oxygen Consumption - drug effects
Patients
Pharmacology. Drug treatments
Pulmonary arteries
Random Allocation
Splanchnic Circulation - drug effects
Surgical apparatus & instruments
Veins & arteries
title Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T02%3A14%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20enoximone%20on%20systemic%20and%20splanchnic%20oxygen%20utilization%20and%20endotoxin%20release%20following%20cardiopulmonary%20bypass&rft.jtitle=Intensive%20care%20medicine&rft.au=LOICK,%20H.%20M&rft.date=1997-03-01&rft.volume=23&rft.issue=3&rft.spage=267&rft.epage=275&rft.pages=267-275&rft.issn=0342-4642&rft.eissn=1432-1238&rft.coden=ICMED9&rft_id=info:doi/10.1007/s001340050327&rft_dat=%3Cproquest_cross%3E78908638%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1012105083&rft_id=info:pmid/9083228&rfr_iscdi=true